Mylan Deal Furthers Pfizer CEO’s Bet on Patent-Protected Drugs – The Wall Street Journal

Mylan Deal Furthers Pfizer CEO’s Bet on Patent-Protected Drugs  The Wall Street Journal

A deal to merge Pfizer Inc.’s off-patent drugs business with generic drugmaker Mylan NV caps new Pfizer Chief Executive Albert Bourla’s remodeling of one of …